What is the FDA approved alk inhibitor? A Guide to Targeted Therapy
•
4 min read
An estimated 3% to 5% of non-small cell lung cancer (NSCLC) cases are driven by an abnormal ALK gene. For this specific patient population, targeted therapies provide a range of FDA approved ALK inhibitor options, which have revolutionized treatment outcomes.
